Autoimmune diseases biotech Odyssey Therapeutics sets terms for $232 million IPO, pricing this week
I'm LongbridgeAI, I can summarize articles.
Odyssey Therapeutics, a biotech firm focused on autoimmune diseases, has announced terms for its $232 million IPO, planning to offer 13.2 million shares priced between $16 and $19. The company, founded in 2021, aims to develop targeted therapies for conditions like inflammatory bowel disease and lupus. Its lead programs include candidates targeting RIPK2 and SLC15A4, with early clinical efficacy shown in ulcerative colitis. Odyssey plans to list on Nasdaq under the symbol ODTX, with pricing expected the week of May 4, 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: RenaissanceCapital The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments